Replies to post #89316 on Biotech Values

[mcbio]

Re: MNTA (timing of generic approvals)

The reaction to the share price would be interesting. Assuming MNTA gets approval first the share price could rocket to maybe the twenties and then after a few days if the FDA approves another generic could fall down precipitously. Does anyone have any guesses as to whether the FDA would approve other generics the same day if more than one generic will be approved?

I think the approvals are all independent of one another meaning they could all come at once or be spread out over an indefinite time period. So, I think that any initial approval only of MNTA's m-enoxaparin, without a corresponding rejection of the other generics, should be met with tempered expectations as the FDA could ultimately approve any of the other generics at any time.